JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Registration Number
- NCT06079983
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Brief Summary
This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy.
The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to:
* Experimental group: JSKN003 monotherapy
* Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy
- Detailed Description
This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy.
The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to:
* Experimental group: JSKN003 monotherapy
* Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 400
-
1. The subject is able to understand the informed consent form, voluntarily participate and sign the informed consent form.
2. The subject ≥ 18 years old on the day of signing the informed consent form, male or female.
3. Unresectable locally recurrent or metastatic breast cancer, previous histopathological reports of HER2 IHC 1+ or 2+ and ISH-, previous histopathological reports have not been diagnosed as HER2 IHC 3+ or 2+ and ISH+.
4. Have received at least 1 to 2 lines of chemotherapy regimens for breast cancer in the relapse/metastatic stage.
5. Willing to provide sufficient archived tumor pathology specimens for central laboratory detection of HER2 status.
6. Documented radiographic disease progression (during or after the most recent treatment).
7. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
8. Expected survival ≥ 3 months. 9. ECOG score of 0 or 1 within 14 days prior to administration. 10. Female subjects of childbearing potential or male subjects of fertile partner consent to use highly effective contraception from the signing of informed consent.
11. Laboratory tests within 14 days before administration and cardiac function tests within 28 days meet the criteria.
12. Have sufficient elution of previous treatment before administration.
-
1. Untreated, or unstable brain parenchymal metastases, spinal cord metastases or compression, cancerous meningitis.
2. Patients with only skin lesions as target lesions. 3. Those with a history of other primary malignant tumors within 5 years before administration.
4. Selection of the control drug by the investigator who is not suitable for the protocol prescribed.
5. Previous use of antibody conjugates containing topoisomerase I inhibitors. 6. There is a third gap fluid that cannot be controlled by drainage, etc. 7. Previous or current interstitial pneumonia/lung disease requiring systemic hormone therapy.
8. Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that affect oral administration and absorption of the drug.
9. Previous or current autoimmune disease. 10. Have uncontrolled comorbidities. 11. The toxicity of previous antitumor therapy has not been restored to grade ≤1 (NCI-CTCAE v5.0).
12. History of previous immunodeficiency. 13. History of life-threatening allergic reactions or known ≥ grade 3 allergy to any component or excipient in the investigational pharmaceutical formulation.
14. Other conditions that the investigators believe will affect the safety or adherence to drug treatment in this study, including but not limited to psychiatric disorders, alcohol or drug abuse.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description The chemotherapy chosen by the investigator Capecitabine tablets The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. The chemotherapy chosen by the investigator Paclitaxel for injection (albumin-bound type) The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. The chemotherapy chosen by the investigator Docetaxel injection The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. The chemotherapy chosen by the investigator Eribulin mesylate injection The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. The chemotherapy chosen by the investigator Gemcitabine hydrochloride for injection The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. The chemotherapy chosen by the investigator Vinorelbine tartrate injection The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization. JSKN003 JSKN003 Administered intravenously according to protocol.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) up to approximately 3 years after the first enrollment PFS evaluated by BICR according to RECIST v1.1 criteria is defined as the time from randomization to the first recorded disease progression or death from any cause as a result of BICR evaluation according to RECIST v1.1 criteria.
- Secondary Outcome Measures
Name Time Method Overall survival（OS） up to approximately 3 years after the first enrollment OS, defined as the time from randomization to death from any cause;
Objective Response Rate (ORR) up to approximately 3 years after the first enrollment BICR and investigators were judged according to RECIST v1.1 criteria ，objective response rate (ORR), defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST v1.1 criteria;
Duration of Response (DOR) up to approximately 3 years after the first enrollment BICR and investigators were judged according to RECIST v1.1 criteria，Duration of response (DoR), defined as the time from the first recorded response (CR/PR) to the first documented disease progression (PD) or death from any cause;
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (87)
Erwei Song
🇨🇳Guangzhou, Guangdong, China
Jiong Wu
🇨🇳Shanghai, Shanghai Municipality, China
Anyang Cancer Hospital
🇨🇳Anyang, China
Affiliated Hospital of Hebei University
🇨🇳Baoding, China
Beijing Luhe Hospital
🇨🇳Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Peking University Cancer Hospital
🇨🇳Beijing, China
The First Affiliated Hospital of China Medical University
🇨🇳Beijing, China
The First Medical Center of the General Hospital of the People's Liberation Army Chinese People's Liberation Army
🇨🇳Beijing, China
Bethune First Hospital of Jilin University
🇨🇳Changchun, China
Scroll for more (77 remaining)Erwei Song🇨🇳Guangzhou, Guangdong, ChinaErwei SongContact